Evaluating of quality of life and functional status in patients with rheumatoid arthritis

Česká verzia

Authors: A. Čalfová ¹; I. Lazúrová ¹; J. Benka ²; Ž. Macejová ³
Authors place of work: I. Interná klinika Lekárskej fakulty UPJŠ a FN L. Pasteura Košice, Slovenská republika, prednostka prof. MUDr. Ivica Lazúrová, CSc. ¹; Katedra pedagogickej psychológie a psychológie zdravia Filozofickej fakulty UPJŠ Košice, Slovenská republika, vedúci katedry PhDr. Beáta Gajdošová, PhD. ²; III. interná klinika Lekárskej fakulty UPJŠ a FN L. Pasteura Košice, Slovenská republika, prednosta prof. MUDr. Daniel Pella, PhD. ³
Published in the journal: Vnitř Lék 2011; 57(2): 170-175
Category: Reviews

Summary

There is a growing worldwide interest for more information regarding morbidity and especially chronic diseases as well as the economical burden which it creates for the disabled individual and the society as a whole. Recently, increased attention has been paid to the scientific assessment of quality of life in chronically ill. Measures of physical and other abilities have shown a great prognostic value regarding disease outcomes. Rheumatoid arthritis (RA) is a chronic, progressive, systemic inflammatory disease which negatively influences quality of life of patients. In rheumatology quality of life is assessed with two types of instruments: generic and specific. Current research has shown that specific measures are more sensitive to treatment induced changes in comparison with the generic measures. However, the choice of an instrument largely depends on the specific goal of the study. Both types of measures have shown strengths and weaknesses and they have been used simultaneously in order to provide a complex evaluation of quality of life.

Key words:
quality of life – rheumatoid arthritis

Zdroje

1. Whalley D, McKenna SP, De Jong Z et al. Quality of life in rheumatoid arthritis. Br J Rheumatol 1997; 36: 884–888.

2. Lapsley HM, March LM, Tribe KL et al. Living with rheumatoid arthritis: expenditures, health status, and social impact on patients. Ann Rheum Dis 2002; 61: 818–821.

3. Borstlap M, van de Laar M, Zant J et al. Components of health: an analysis in rheumatoid arthritis using quality of life questionnaires and clinical and laboratory variables. Ann Rheum Dis 1993; 52: 650–654.

4. Russell AS. Quality-of-life assessment in rheumatoid arthritis. Pharmacoeconomics 2008; 26: 831–846.

5. Bowling A. Measuring disease. New York: McGraw-Hill Companies 2001: 224–246.

6. Macejová Ž, Nagyová I, Szilasiová A et al. Bolesť a reumatoidná artritída. Vnitř Lék 1999; 45: 359–363.

7. Suurmeijer TP, Doeglas DM, Moum T et al. The Groningen Activity Restriction Scale for measuring disability: its utility in international comparisons. Am J Public Health 1994; 84: 1270–1273.

8. Bowling A. Measuring health. New York: McGraw-Hill Companies 2005: 19–42.

9. Karnofsky DA, Burchenal JH. The clinical evaluation of chemotherapeutic agents in cancer. New York: Columbia University Press 1949: 191–205.

10. Szilasiová A, Macejová Ž, Kovařová M et al. Posúdenie výkonnostného stavu chorých s reumatoidnou artritídou pomocou Karnofského mierky. Rheumatologia 1998; 12: 65–69.

11. Yilmaz F, Sahin F, Ergoz E et al. Quality of life assessments with SF 36 in different musculoskeletal diseases. Clin Rheumatol 2008; 27: 327–332.

12. Steinbrocker O, Traeger CH, Battermen RC. Therapeutic criteria in rheumatoid arthritis. J Am Med Assoc 1949; 140: 659–662.

13. Bruce B, Fries JF. The Health Assessment Questionnaire (HAQ). Clin Exp Rheumatol 2005; 23 (5 Suppl 39): S14–S18.

14. Bruce B, Fries JF. The Stanford Health Assessment Questionnaire: a review of its history, issues, progress, and documentation. J Rheumatol 2003; 30: 167–178.

15. Greenwood MC, Doyle DV, Ensor M. Does the Stanford Health Assessment Questionnaire have potential as a monitoring tool for subjects with rheumatoid arthritis? Ann Rheum Dis 2001; 60: 344–348.

16. Sokka T, Häkkinen A, Krishnan E et al. Similar prediction of mortality by the health assessment questionnaire in patients with rheumatoid arthritis and the general population. Ann Rheum Dis 2004; 63: 494–497.

17. Ziebland S, Fitzpatrick R, Jenkinson C et al. Comparison of two approaches to measuring change in health status in rheumatoid arthritis: the Health Assessment Questionnaire (HAQ) and modified HAQ. Ann Rheum Dis 1992; 51: 1202–1205.

18. Guillemin F, Suurmeijer T, Krol B et al. Functional disability in early rheumatoid arthritis: description and risk factors. J Rheumatol 1994; 21: 1051–1055.

19. Wolfe F, Kleinheksel SM, Cathey MA et al. The clinical value of the Stanford Health Assessment Questionnaire Functional Disability Index in patients with rheumatoid arthritis. J Rheumatol 1988; 15: 1480–1488.

20. Szilasiová A, Kovařová M, Macejová Ž et al. Funkčné hodnotenie chorých so včasnou reumatoidnou artritídou. Rheumatologia 1997; 11: 205–211.

21. de Jong Z, van der Heijde D, McKenna SPet al. The reliability and construct validity of the RAQoL: a rheumatoid arthritis-specific quality of life instrument. Br J Rheumatol 1997; 36: 878–883.

22. Tijhuis GJ, de Jong Z, Zwinderman AH et al. The validity of the Rheumatoid Arthritis Quality of Life (RAQoL) questionnaire. Rheumatology 2001; 40: 1112–1119.

23. Tugwell P, Wells G, Strand V et al. Clinical improvement as reflected in measures of function and health-related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis: sensitivity and relative efficiency to detect a treatment effect in a twelve-month, placebo-controlled trial. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis Rheum 2000; 43: 506–514.

24. Linde L, Sørensen J, Ostergaard M et al. Health-related quality of life: validity, reliability, and responsiveness of SF-36, EQ-15D, EQ-5D, RAQoL, and HAQ in patients with rheumatoid arthritis. J Rheumatol 2008; 35: 1528–1537.

25. Szilasiová A, Macejová Ž, Nagyová I et al. Reliabilita a validita slovenskej verzie a modifikácia Stanfordského dotazníka hodnotiaceho zdravie pomocou indexu disability (HAQ) u pacientov s reumatoidnou artritídou. Vnitř Lék 2002; 47: 8–16.

26. Wiebe S, Guyatt G, Weaver B et al. Comparative responsiveness of generic and specific quality-of-life instruments. J Clin Epidemiol 2003; 56: 52–60.

27. Macejová Ž, Oetterová M, Rybár I et al. Zlepšenie kvality života pacientov s reumatoidnou artritídou po účinnej liečbe. Rheumatologia 2007; 21: 83–86.